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Abstract
Background: Metabolic reprogramming resulting in enhanced glycolysis is a phenotypic trait of cancer cells, which is
imposed by the tumor microenvironment and is linked to the down-regulation of the catalytic subunit of the
mitochondrial H+-ATPase (b-F1-ATPase). The bioenergetic signature is a protein ratio (b-F1-ATPase/GAPDH), which
provides an estimate of glucose metabolism in tumors and serves as a prognostic indicator for cancer patients. Targeting
energetic metabolism could be a viable alternative to conventional anticancer chemotherapies. Herein, we document
that the bioenergetic signature of isogenic colon cancer cells provides a gauge to predict the cell-death response to the
metabolic inhibitors, 3-bromopyruvate (3BrP) and iodoacetate (IA), and the anti-metabolite, 5-fluorouracil (5-FU).
Methods: The bioenergetic signature of the cells was determined by western blotting. Aerobic glycolysis was
determined from lactate production rates. The cell death was analyzed by fluorescence microscopy and flow
cytometry. Cellular ATP concentrations were determined using bioluminiscence. Pearson’s correlation coefficient
was applied to assess the relationship between the bioenergetic signature and the cell death response. In vivo
tumor regression activities of the compounds were assessed using a xenograft mouse model injected with the
highly glycolytic HCT116 colocarcinoma cells.
Results: We demonstrate that the bioenergetic signature of isogenic HCT116 cancer cells inversely correlates with
the potential to execute necrosis in response to 3BrP or IA treatment. Conversely, the bioenergetic signature directly
correlates with the potential to execute apoptosis in response to 5-FU treatment in the same cells. However,
despite the large differences observed in the in vitro cell-death responses associated with 3BrP, IA and 5-FU, the in
vivo tumor regression activities of these agents were comparable.
Conclusions: Overall, we suggest that the determination of the bioenergetic signature of colon carcinomas could
provide a tool for predicting the therapeutic response to various chemotherapeutic strategies aimed at combating
tumor progression.
Background
Colorectal cancer (CRC) is a common neoplasia which
poses a heavy burden on public health systems world-
wide [1]. Despite the establishment of CRC screening
protocols, tailored therapeutic approaches are required
to minimize the significant social impact of this disease
[1]. At present, KRAS mutation status is the only vali-
dated predictive marker for targeted CRC therapy [2].
Thus, the development and clinical implementation of
new predictive molecular markers are needed to aid in
the selection of patients likely to respond to therapy and
rationalized CRC treatments [2].
Cancer cells and tumors have a predominant glycolytic
metabolism, even under aerobic conditions [3,4].
Although the altered energetic metabolism of cancer
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cells has been proposed as a potential target for cancer
treatment [3,5-7], it could also represent a therapeutic
obstacle, because of its contribution to chemo- and
radio-resistance [8]. In some tumors, this glycolytic phe-
notype is accompanied by a loss of bioenergetic activity
in mitochondria [9,10], which can be estimated by
determining its bioenergetic signature [10,11]. The bioe-
nergetic signature is a protein ratio (b-F1-ATPase/
GAPDH ratio) that assesses the expression of the cataly-
tic subunit of mitochondrial H+-ATP synthase (b-F1-
ATPase), a bottle-neck component required for the
synthesis of biological energy, relative to the expression
of glycolytic glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) [10]. Consistently, the bioenergetic signature
has been observed to be significantly down-regulated in
different human tumors compared to paired normal tis-
sues [10,12-19]. Recent findings indicate that the bioe-
nergetic signature also represents a functional index of
metabolic activity because it correlates, both in vivo and
in vitro, with the rate of glucose utilization by cancer
cells and tumors [9,11]. Moreover, according to large
cohort studies of colon [10,19], lung [9,14] and breast
[16,20] cancer patients, low tumor bioenergetic signa-
tures are associated with poor patient prognosis,
strongly suggesting that impaired mitochondrial bioe-
nergetics is at the heart of cancer progression.
Remarkably, down-regulation of b-F1-ATPase has
been widely associated with the resistance of cancer
cells to standard anticancer therapies [21-23]. In the
specific case of colon cancer cells, chemotherapeutic
response to 5-fluorouracil (5-FU) [11,21], as well as sev-
eral metabolic inhibitors [23,24], was assessed in cells
with different genetic backgrounds: a condition that is
likely to affect the cellular response to chemotherapeutic
agents. The recent development of isogenic HCT116
colon cancer cell lines, representing different bioener-
getic signatures [11], has provided an opportunity to
unambiguously assess the influence of energetic metabo-
lism on colon cancer therapy. In this study, we investi-
gated cell death responses in metabolically different
isogenic HCT116 cells and the regression of tumor
xenographs, in response to the glycolytic inhibitors 3-
bromopyruvate (3BrP) and iodoacetate (IA), and the
classic chemotherapeutic agent, 5-FU. The small alkylat-
ing 3BrP and IA target the enzymes of glycolysis hexoki-
nase [25] and GAPDH [26], respectively, although recent
findings suggest that 3BrP also targets GAPDH [27].
Methods
Cell cultures and treatments
Human colorectal carcinoma HCT116 cells were grown
in McCoy’s 5A media supplemented with 10% fetal
bovine serum. Twenty four h after seeding, cells were
left untreated (M-type), treated with 6 μM oligomycin
(G-type), or treated with 10 mM 2-DG (SM-type) for
48h. On the day of the experiment, culture medium was
replaced without the addition of any drug and cells were
used at ~ 60% confluence for experiments. Where indi-
cated, cells were incubated with 10 μM 5-FU for 48h, or
8 μM 3BrP or 100 μM IA for 7h.
Protein electrophoresis and Western blot analysis
Cells were resuspended in lysis buffer (25 mM Hepes,
2.5 mM EDTA, 1% Triton X-100, 1 mM PMSF and
5 μg/mL leupeptin). Cell lysates were clarified by centri-
fugation at 11000 × g for 15 min. Resulting supernatants
were fractionated on SDS-PAGE and transferred onto
PVDF membranes for immunoblot analysis (Inmobilon-
P, Millipore). Protein concentrations were determined
using Bradford reagent (Bio-Rad protein assay). The pri-
mary monoclonal antibodies used were: anti-Hsp60
(Stressgene SPA-807, 1:2000) and anti-GAPDH (Abcam,
1:20000). The polyclonal rabbit anti-b-F1-ATPase
(1:15000) [10] was also used. Peroxidase-conjugated
anti-mouse or anti-rabbit IgGs (Nordic Immunonology,
1: 3000) were used as secondary antibodies. The blots
were developed using the ECL reagent.
Aerobic glycolysis
For determination of the rates of aerobic glycolysis,
0.1 mL aliquots of culture media were collected and
used for enzymatic determination of lactate [11].
Cell death assays
Exposure of phosphatidylserine on the cell surface was
analyzed after various cellular treatments using the
annexin V-FITC assay (Sigma-Aldrich). Briefly, cells
were washed twice in PBS and incubated in the dark for
10 min at room temperature with FITC-conjugated
annexin-V (50 μg/mL) and propidium iodide (100 μg/
mL) solutions. For each analysis, 10,000 events were
recorded in a FACScan (Becton-Dickinson). Cell death
was also determined using fluorescence microscopy. In
brief, cells treated with the different compounds
described were harvested, washed with PBS and incu-
bated in the dark for 5 min at room temperature with
Hoechst 33342 (1 mg/mL) and propidium iodide (1 mg/
mL) solutions. After washing, samples were observed
under a Leica DM-IRB fluorescence microscope (UV).
The percentage of dead (red stained) cells was calculated
from 10-20 different randomly selected fields for each
condition assayed.
Caspase activity assays
Caspase 3/7 activity was determined using the lumino-
genic Ac-DEVD-pNA substrate included in the caspase-
Glo 3/7 assay kit, according to the manufacturer’s
instructions (Promega). The reaction product was
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detected at 405 nm using a FLUOstar OPTIMA (BMG
Labtech) plate luminometer.
Determination of ATP
Approximately 6 × 104 cells were seeded and treated as
indicated. Cellular ATP concentrations were determined
using an ATP Bioluminiscence Assay Kit (Roche).
In vivo tumorigenesis and treatments
Approximately, 1 × 107 G-type HCT116 cells were
injected into the flank of 6-week-old male nude mice
(National Cancer Institute, Frederick, Maryland). Tumor
size was determined using a standard caliper and tumor
volume was calculated using the formula: (width2 ×
length) × 0.52, where width represents the shortest
dimension of the tumor [11]. Twenty days after tumor
induction, when tumors reached ~ 1,000 mm3 of
volume, animals were randomly allocated into four dif-
ferent groups for daily intraperitoneal injections (100
μL) with inhibitors of glycolysis (8 μM 3BrP or 100 μM
IA), a conventional treatment for colon cancer (0.5 mM
5-FU) or 0.9% NaCl as a control group. All treatments
were performed for six consecutive days. Following
treatment, animals were weighted and killed and the
tumors extracted. All animal experiments were con-
ducted according to the ethical rules established by the
Universidad Autónoma de Madrid Review Board.
Statistical analysis
Statistical analysis was performed by Student’s t test.
Statistical tests were two-sided at the 5% level of signifi-
cance. Pearson’s correlation coefficient, p-value (p) and
ANOVA with post hoc test (Dunnett’s test) were calcu-
lated using the SPSS 17.0 software package.
Results
Because of the regulated expression of b-F1-ATPase,
development of HCT116 colon cancer cell lines, display-
ing low (G-cells), medium (M-cells) or high (SM-cells)
bioenergetic signatures (see Figure 1, and additional file 1)
was accomplished by modification of cell culture con-
ditions [11]. As recently detailed [11], the bioenergetic
signature of each cell line was found to inversely corre-
late with the rate of aerobic glycolysis, where G-cells >
M-cells > SM-cells (Figure 1A-C). Evaluation of cell
death responses were assessed using fluorescence micro-
scopy after double labeling with Hoechst 33342 and
propidium iodide (PI) (Figure 1A-C). Our results show
that death responses (% PI positive cells) to both meta-
bolic inhibitors (3BrP and IA) decreased as the bioener-
getic signature of the cells increased. Thus, the lower
the bioenergetic signature of a cell the greater the death
response to the glycolytic inhibitor treatment (G > M >
SM) (Figure 1D). In fact, significant inverse correlations
were uncovered between the bioenergetic signature of a
cell and the extent of cell death following 3BrP (R =
-0.633; n = 36, P < 0.01) and IA (R = -0.616; n = 36, P
< 0.01) treatment, supporting the relevance of these gly-
colytic inhibitors in cancer treatment [7,23]. Specifically,
in M-cells, 3BrP treatment was more effective than IA
treatment at triggering cell death (Figure 1). In contrast,
cell death in response to 5-FU treatment was found to
directly correlate with bioenergetic signature (R = 0.519;
n = 27, P < 0.01) (Figure 1D): as the activity of aerobic
glycolysis is diminished cell death in response to 5-FU
treatment is augmented (SM-cells > M-cells > G-cells),
suggesting the participation of mitochondrial oxidative
phosphorylation in the mechanism of 5-FU mediated
cell death.
Flow cytometric analysis of plasma membrane exposure
of phosphatidylserine (detected using an annexin V-
FITC assay) was used as an index of apoptotic (annexin-
positive) versus necrotic (PI positive) cell death [28]
(Figure 2). This approach enables simultaneous estima-
tion of the cell death pathway preferentially induced by
each type of treatment. Upon treatment with the meta-
bolic inhibitors 3BrP and IA, G-, M- and SM-cells all
display a very large increase in the percentage of PI-
positive cells (coupled with the absence of relevant
changes in the percentage of annexin-positive cells) and
thus appear to die by necrosis (Figure 2) [29,30]. In
agreement with these results, no activation of caspase 3
(an apoptotic indicator) was observed following any of
these above treatments in any of the cell lines tested
(data not shown). Therefore, inhibition of the activity of
glycolytic enzymes appears to trigger necrotic cell death.
Furthermore, this effect was observed to be more pro-
nounced in cells that rely more heavily on glycolysis as
a pathway for energy provision. In contrast, 5-FU treat-
ment of G-, M- and especially SM-cells resulted in a sig-
nificant percentage of annexin-positive stained cells
compared to controls (Figure 2), suggesting induction of
apoptosis in response to 5-FU treatment. Importantly,
this induction of apoptosis following 5-FU treatment
appears to be more pronounced in cells that rely less
heavily on glycolysis. In agreement with this finding,
caspase 3 activity was found to be significantly increased
in 5-FU treated SM-cells (1.0 ± 0.2 vs. 2.2 ± 0.1 a.u./
15000 cells for control and 5-FU treated cells, respec-
tively, P < 0.05). Therefore, efficient activation of apop-
tosis following 5-FU treatment may be associated with
cellular reliance on mitochondrial energetic metabolism
for cellular energy provision, in agreement with previous
reports [11,21,31].
To further confirm the cell death pathway activated in
response to each of the treatments studied cellular ATP
concentrations were determined (Figure 3). We observed
that treatment of cells with 3BrP or IA was associated
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Figure 1 The Bioenergetic Signature correlates with the cell-death response to chemotherapy . HCT116 cells were treated as indicated
[11] to produce cells with low (G-cells) (A), medium (M-cells) (B) and high (SM-cells) (C) bioenergetic signatures (b-F1/GAPDH ratio). The rates of
aerobic glycolysis in G-, M- and SM-cells are also indicated. Cells were exposed to the following agents: 8 μM 3BrP, 100 μM IA, 10 μM 5-FU or
were left untreated (Control). Cells were double-stained with Hoechst 33342 and propidium iodide and visualized using fluorescence microscopy
at 20x magnification. The percentage of dead cells (red cells, PI positive) was determined by examination of different randomly selected fields.
Histograms shown (A-C) represent the means ± SEM of 10-25, 10-24 and 10-23 independent determinations in G-, M-, and SM-cells respectively.
*, P < 0.05 for multiple comparisons by ANOVA and post hoc Dunnett’s test. Plots in (D) illustrate the inverse (3BrP and IA) and direct (5-FU)
correlation that exists between the bioenergetic signature of the cells and the death-response to the chemotherapeutic agents.
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Figure 2 The Bioenergetic Signature correlates with the cell-death pathway in response to chemotherapy . HCT116 cells were treated as
indicated [11] to produce cells with low (G-cells), medium (M-cells) and high (SM-cells) bioenergetic signatures. Cells were then treated with the
following agents: 8 μM 3BrP, 100 μM IA, 10 μM 5-FU or left untreated (Control). A, Representative FACS analysis of cells after annexinV-FITC (50
μg/mL) and propidium iodide (100 μg/mL) staining are shown. The lower left quadrant corresponds to viable cells; the lower right quadrant
early-apoptotic (annexin-positive) cells and the upper right and left quadrants corresponds to dead (PI positive) cells. Histograms shown are the
means ± SEM of the percentage of apoptotic (annexin V positive) (B) and necrotic (PI positive) cells (C) from 4-6 independent determinations in
G- (open bars), M- (closed bars) and SM-cells (hatched bars). *, p < 0.05 for multiple comparisons by ANOVA and post hoc Dunnett’s test.
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Figure 3 Cellular ATP concentrations in response to chemotherapy . HCT116 cells were treated as indicated [11] to produce cells with low
(G-cells), medium (M-cells) and high (SM-cells) bioenergetic signature. Cells were then treated with the following agents: 8 μM 3BrP, 100 μM IA,
10 μM 5-FU or left untreated (Control) and ATP concentrations were determined. Histograms shown are means ± SEM. *, p < 0.05 compared to
controls by Student’s t test. ns, no significant.
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with a very large depletion of cellular ATP concentra-
tions in all cell lineages (Figure 3), consistent with activa-
tion of necrosis by metabolic catastrophe in response to
treatment with these metabolic inhibitors. In contrast,
treatment of cells with 5-FU only marginally affected cel-
lular ATP concentrations in G- and M-cells (Figure 3)
and slightly, but significantly, promoted a 50% reduction
in cellular ATP concentrations in SM-cells (Figure 3),
indicating the absence of a compromised metabolic state
following 5-FU treatment.
Previous findings have suggested that only highly gly-
colytic G-cells are able to develop tumors in nude mice
[11]. Therefore, in order to test the in vivo tumor
regression activity of the metabolic inhibitors analyzed
in vitro, animals were implanted with G-cells. Animals
that developed ~ 1 cm3 tumors were treated with daily
doses of 8 μM 3BrP, 100 μM IA or 0.5 mM 5-FU over
six consecutive days (Figure 4A). A control NaCl-treated
group was also included for comparison (Figure 4A).
Interestingly, from both a macroscopic (Figure 4B) and
behavioral point of view, all treatments tested (except
controls) seemed to affect the mice in a similar manner.
Specifically, control animals developed a rapid 2.5-fold
increase in tumor volume during the treatment period
(Figure 4A). In contrast, animals treated with either
5-FU or IA revealed a significant ~ 30% decrease in
tumor volume after 6 days of treatment (Figure 4A),
while maximum tumor regression (> 50%) was observed
in mice treated with 3BrP (Figure 4A), consistent with
the higher cell-death trend associated with 3BrP treat-
ment in vitro (Figure 1). However, the large differences
in cell death triggered by 3BrP and IA compared to
5-FU in G-type cells (Figure 1A) were largely absent fol-
lowing in vivo treatments despite the fact that the
tumors had a G-phenotype [11]. These results suggest
that additional mechanisms may play a role in promot-
ing tumor regression in vivo and that in vitro data
should be extrapolated with caution.
Discussion
In an effort to translate the bioenergetic signature to
clinical practice, we have recently developed monoclonal
antibodies against various markers of energetic metabo-
lism [32]. We found that cancer abolishes cell-type spe-
cific differences in the bioenergetic signature [32],
supporting its use as a generic target to combat different
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Figure 4 Metabolic inhibitors effectively promote tumor regression . HCT116 cells (107 cells per animal) with low bioenergetic signature (G-
cells) were injected into nude mice for tumor development. Twenty days after, when tumor volume reached ~1 cm3, the animals received daily
100 μL intraperitoneal injections, containing 8 μM 3BrP (n = 10, open square), 0.5 mM 5-FU (n = 5, grey square) or 100 μM IA (n = 7, closed
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is presented normalized to its volume before initiation of the treatments. * and #, p < 0.05 when comparing 3BrP with 5-FU- and IA-treated
mice, respectively. **, p < 0.05 for multiple comparisons by ANOVA. Inserts provide representative examples of the differences in tumor size
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neoplasias [32]. Indeed, b-F1-ATPase expression has
been shown to be a therapeutic response marker in dif-
ferent cancer cell lines, both for single and combined
chemotherapy [19,21-24,33]. In the present study, we
document the correlation between the bioenergetic sig-
nature of a cell, which represents an index of the rela-
tive relevance of cellular energy provision pathways
[9,11], and the potential to execute cell death in
response to the metabolic inhibitors, 3BrP and IA, and
the anti-metabolite 5-FU. The correlations observed in
this study cannot be ascribed to differences in the
genetic background of the cells because: (i) all of the
cells were derived from the same parental HCT116 cells
and (ii) the energetic metabolism of HCT116 cells is a
reversible phenotypic trait amenable to regulation
[11,34]. Furthermore, although some cancer cells can
oxidize glutamine for energy production purposes [3-5],
glutamine contributes very little to the energetic meta-
bolism of the highly glycolytic HCT116 cells used in
this study. In fact, oxygen consumption rates, aerobic
glycolysis rates and the bioenergetic signature of
HCT116 cells are not affected by the presence of gluta-
mine in the culture medium (see additional file 2).
Mechanistically, we propose that the cell death and
tumor regression observed following administration of
glycolytic inhibitors (3BrP and IA) may be due to induc-
tion of necrosis, whereas the cell death activity observed
upon 5-FU treatment may occur through apoptosis (Fig-
ures 2 and 3). This later finding is consistent with the
relevant roles played by oxidative phosphorylation [35]
and mitochondrial H+-ATP synthase activity [33,36] in
the efficient execution of cell death. Indeed, the bioener-
getic activity of mitochondria in colon cancer cells
[11,21] and tumors [19], has been associated with the
ability to execute a ROS-mediated cell death response
upon 5-FU treatment [11].
On the other hand, small alkylating agents have been
shown to be able to kill cancer cells resistant to apopto-
sis by a process known as “programmed necrosis”
through depletion of NAD+ via PARP1 activation [30].
However, the induction of necrosis in response to the
glycolytic inhibitors 3BrP and IA is exerted indepen-
dently of PARP1 processing (data not shown), and most
likely results from a metabolic catastrophe due to cellu-
lar ATP depletion (Figure 3) [23,24]. Overall, our studies
suggest that the enzymes of glycolysis could represent
therapeutic targets for the treatment of colon cancer
that may be as effective as conventional treatments
(5-FU) at promoting tumor regression, in agreement
with findings by others [25,37].
The use of glycolytic inhibitors as chemotherapeutic
agents has pros and contras. One problem is the deleter-
ious effects that these agents could trigger in cell types
strictly dependent on aerobic glycolysis for energy (e.g.
neurons, lymphocytes, erythrocytes, retina, renal
medulla, etc). However, glycolytic enzymes do have
highly specific active site residues that, in principle,
could provide more specific drug targets than those of
proteins involved in signal transduction pathways. Thus,
the use of such inhibitors may be beneficial in combina-
tion therapy as enhancers of the action of current che-
motherapeutic drugs [7,23]. Targeting energetic
metabolism might represent an alternative cancer treat-
ment route in the near future, because tumor cells that
are resistant to chemotherapy could effectively die by
necrosis in response to different metabolic inhibitors.
Whatever the case, the bioenergetic signature offers a
reliable gauge to predict the cell death response (apop-
totic or necrotic cell death) to cancer therapy.
Conclusions
In summary, we have demonstrated that the bioenergetic
signature of colon cancer cells inversely correlates with
the potential to execute necrosis in response to treat-
ments with glycolytic inhibitors. In contrast, the bioener-
getic signature directly correlates with the apoptotic
response to 5-FU treatment. Overall, our results support
the use of the bioenergetic signature as a gauge for pre-
dicting cell death in response to different therapeutic
strategies in colon cancer.
Additional material
Additional file 1: The bioenergetic signature of HCT116-derived cell
lines. Representative western blot analysis. Representative western
blots of the expression of b-F1-ATPase, Hsp60 and GAPDH in two
different preparations (lanes 1-2) of (A) 2DG-treated (SM) and (B) OL-
treated (G) cells when compared to non-treated (M) HCT116 cells.
Additional file 2: Effect of glutamine (Gln) in the energetic
metabolism of HCT116 cells. (A) Representative western blots of the
expression of b- F1-ATPase, Hsp60 and GAPDH in two different
preparations of HCT116 cells grown in the presence (+) or absence (-) of
glutamine (Gln). The histogram illustrates the bioenergetic signature (b-F1/
GAPDH ratio) in the presence (open bar) or absence (closed bar) of
glutamine. (B) HCT116 cells were processed for the determination of the
rates of aerobic glycolysis in the presence (open bar) or absence (closed
bar) of glutamine. The rates of aerobic glycolysis were also determined
after the addition of 6 μM oligomycin (hatched bars). (C) Determination
of the rates of oxygen consumption. The results shown are the mean ±
SEM of 6-15 independent determinations. No statistical significant
differences were observed by Student’s t-test in any of the parameters
determined.
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